Literature DB >> 22104426

Acute or chronic life-threatening diseases associated with Epstein-Barr virus infection.

Motohiko Okano1, Thomas G Gross.   

Abstract

Infectious mononucleosis (IM) is one of the representative, usually benign, acute diseases associated with primary Epstein-Barr virus (EBV) infection. IM is generally self-limiting and is characterized mostly by transient fever, lymphadenopathy and hepatosplenomegaly. However, very rarely primary EBV infection results in severe or fatal conditions such as hemophagocytic lymphohistiocytosis together with fulminant hepatitis designated as severe or fatal IM or EBV-associated hemophagocytic lymphohistiocytosis alone. In addition, chronic EBV-associated diseases include Burkitt's lymphoma, undifferentiated nasopharyngeal carcinoma, Hodgkin lymphoma, T-cell lymphoproliferative disorder (LPD)/lymphoma, natural killer-cell LPD including leukemia or lymphoma, gastric carcinoma, pyothorax-associated lymphoma and senile B-cell LPD as well as chronic active EBV infection and LPD/lymphoma in patients with immunodeficiency. The number of chronic life-threatening diseases linked to the EBV infection is increasingly reported and many of these diseases have a poor prognosis. This review will focus on the historical, pathogenetic, diagnostic, therapeutic and prophylactic issues of EBV-associated life-threatening diseases.

Entities:  

Mesh:

Year:  2012        PMID: 22104426     DOI: 10.1097/MAJ.0b013e318236e02d

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  13 in total

1.  Lymphoma Mimicking Chronic Active Epstein-Barr Virus: A Case Report.

Authors:  Rohini Bahethi; Mingyang Gray; Christian Salib; Ilya Likhterov
Journal:  Head Neck Pathol       Date:  2020-04-29

Review 2.  How virus persistence can initiate the tumorigenesis process.

Authors:  Simone Avanzi; Gualtiero Alvisi; Alessandro Ripalti
Journal:  World J Virol       Date:  2013-05-12

3.  Convergence of non-communicable and infectious diseases in low- and middle-income countries.

Authors:  Justin V Remais; Guang Zeng; Guangwei Li; Lulu Tian; Michael M Engelgau
Journal:  Int J Epidemiol       Date:  2012-10-13       Impact factor: 7.196

4.  Infectious mononucleosis and risk of breast cancer in a prospective study of women.

Authors:  J Massa; A Hamdan; K C Simon; K Bertrand; G Wulf; R M Tamimi; A Ascherio
Journal:  Cancer Causes Control       Date:  2012-10-07       Impact factor: 2.532

Review 5.  Host genetics of Epstein-Barr virus infection, latency and disease.

Authors:  Charlotte J Houldcroft; Paul Kellam
Journal:  Rev Med Virol       Date:  2014-11-27       Impact factor: 6.989

6.  Primary Epstein-Barr virus infection diffusing F18-fluorodeoxyglucose-positron emission tomography/computed tomography response monitoring of Hodgkin's disease: a case report.

Authors:  Hans Balink; Mels Hoogendoorn
Journal:  J Med Case Rep       Date:  2014-06-20

7.  High Levels of EBV-Encoded RNA 1 (EBER1) Trigger Interferon and Inflammation-Related Genes in Keratinocytes Expressing HPV16 E6/E7.

Authors:  Sirinart Aromseree; Jaap M Middeldorp; Chamsai Pientong; Monique van Eijndhoven; Octavia Ramayanti; Sinéad M Lougheed; D Michiel Pegtel; Renske D M Steenbergen; Tipaya Ekalaksananan
Journal:  PLoS One       Date:  2017-01-05       Impact factor: 3.240

8.  Haemophagocytic lymphohistiocytosis associated with fulminant hepatitis and multiorgan failure following primary Epstein-Barr virus and herpes simplex virus type 1 infection.

Authors:  Claudia Honsig; Sandra Beinhardt; Josef Tomasits; Hans Peter Dienes
Journal:  BMJ Case Rep       Date:  2017-03-29

Review 9.  Therapeutic implications of Epstein-Barr virus infection for the treatment of nasopharyngeal carcinoma.

Authors:  Susanna Hilda Hutajulu; Johan Kurnianda; I Bing Tan; Jaap M Middeldorp
Journal:  Ther Clin Risk Manag       Date:  2014-09-05       Impact factor: 2.423

10.  Identification of Epstein-Barr Virus in the Human Placenta and Its Pathologic Characteristics.

Authors:  Younghoon Kim; Hye Sung Kim; Joong Shin Park; Chong Jai Kim; Woo Ho Kim
Journal:  J Korean Med Sci       Date:  2017-12       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.